CM
TTPH

Crestline Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Crestline Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,070
Closed -$1.15M – 191
2017
Q2 		$1.15M Buy
8,070
+5,407
+203% +$836K 0.15% 72
2017
Q1 		$489K Buy
+2,663
New +$299K 0.09% 86

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crestline Management's TTPH Position: Q3 2017 in Review

Crestline Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2017, closing a stake of 8,070 shares — an estimated $1.15M sold.

Crestline Management first reported a position in TTPH in Q1 2017 and held it in 2 quarters. The position peaked at $1.15M in Q2 2017. 94 funds tracked by Wall St. Rank hold TTPH as of Q3 2017.

  • Crestline Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 8,070 Tetraphase Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.15M.
  • Crestline Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
  • Crestline Management's Tetraphase Pharmaceuticals, Inc. position peaked at $1.15M in Q2 2017.
  • 94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.